AI Article Synopsis
- Almotriptan is a highly selective 5-HT1B/1D receptor agonist developed for migraine treatment, with varying absorption rates observed in animal studies – 69.1% in rats and 100% in dogs.
- The drug shows variable absolute bioavailability due to different absorption and metabolism processes, with an elimination half-life ranging from 0.7 to 3 hours.
- In both rats and dogs, urine was the primary route of elimination, with key metabolites differing between species, highlighting the complexity of almotriptan's metabolism.
Article Abstract
Almotriptan is a new highly potent selective 5-HT1B/1D receptor agonist developed for the treatment of migraine, and the disposition of almotriptan in different animal species is now addressed in the current study. Almotriptan was well absorbed in rats (69.1%) and dogs (100%) following oral treatment. The absolute bioavailability was variable reflecting different degrees of absorption and first-pass metabolism (18.7-79.6%). The elimination half-life was short and ranged between 0.7 and 3 h. The main route of elimination of almotriptan was urine with 75.6% and 80.4% of the dose recovered over a 168-h period in rats and dogs, respectively. The gamma-aminobutyric acid metabolite formed by oxidation of the pyrrolidine ring was the main metabolite found in urine, faeces, bile, and plasma of rats and in monkey urine. By contrast, the unchanged drug, the indole acetic acid metabolite formed by oxidative deamination of the dimethylaminoethyl group, and the N-oxide metabolite were the main metabolites in dog.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/00498250600802508 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discovery of a Novel p38α-MK2 Complex Inhibitor as a Potential Choice for Autoimmune Diseases.
J Med Chem
January 2025
Chemical Pharmaceutical Research Center, Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai 200120, P.R. China.
The p38α-MK2 signaling axis plays an important role in the inflammatory response of cells. Here, we carried out a series of optimizations on CDD-450, aiming to enhance inhibition of the p38α-MK2 complex and improve pharmacokinetic properties. First, the magic F strategy was utilized to obtain compound , which displayed a 60-fold increase in tumor necrosis factor α inhibition and a 600-fold increase in interleukin-6 inhibition.
View Article and Find Full Text PDFBackground: SUVN-I7016031 is a novel and selective positive allosteric modulator (PAM) of the M1 subtype of the muscarinic acetylcholine receptors (mAChRs). The proposed primary indication for SUVN-I7016031 is in the treatment of dementia such as Alzheimer's disease dementia (ADD) and Parkinson's disease dementia (PDD). In the current research, the pharmacological properties of SUVN-I7016031 in various types of dementia were investigated.
View Article and Find Full Text PDFPrevalence of Multiple RNA Virus Infections in Nine Types of Commonly Used Laboratory Animals in China.
Zoonoses Public Health
January 2025
Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, People's Republic of China.
Introduction: Laboratory animals are widely used in biomedical research. Surveillance of naturally occurring virus in laboratory animals is important to fully understand the results of animal experiment, control laboratory-acquired infections among research personnel and manage viral transmission within laboratory animal populations. This study aimed to investigate the prevalence of multiple RNA viruses in laboratory animals commonly used in China.
View Article and Find Full Text PDFPrediction of SPT-07A Pharmacokinetics in Rats, Dogs, and Humans Using a Physiologically-Based Pharmacokinetic Model and In Vitro Data.
Pharmaceutics
December 2024
Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, China.
SPT-07A, a D-borneol, is currently being developed in China for the treatment of ischemic stroke. We aimed to create a whole-body physiologically-based pharmacokinetic (PBPK) model to predict the pharmacokinetics of SPT-07A in rats, dogs, and humans. The in vitro metabolism of SPT-07A was studied using hepatic, renal, and intestinal microsomes.
View Article and Find Full Text PDFImpact of Species and Tissue Differences on In Vitro Glucuronidation of Diclofenac.
Molecules
December 2024
Department of Pharmaceutical Science, College of Pharmacy and Health Sciences, Texas Southern University, 3100 Cleburne Street, Houston, TX 77004, USA.
Background: The aim of this study is to determine the impact of species and tissue differences on the glucuronidation of diclofenac in vitro.
Method: Microsomes from different species (rat, monkey, mouse, dog, and human) and rat and human tissues (liver, intestine, and kidney) were used to assess the rate of glucuronidation reaction of diclofenac. The metabolites were quantified using ultra high-performance liquid chromatography (UHPLC) and fitted into a Michaelis-Menten model to determine the metabolic kinetic parameters.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!